Skip to main content
Erschienen in: The European Journal of Health Economics 1/2004

01.02.2004 | Commentary

Do costs of varicella justify routine infant vaccination?

Pharmacoeconomic and clinical considerations

verfasst von: M. J. Postma, J. M. Bos, R. Welte, R. de Groot, W. Luytjes, H. C. Rümke, P. Beutels

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Excerpt

In the European Journal of Health Economics Banz et al. [1] now demonstrate that varicella (chickenpox) causes a significant burden for the German society. Varicella, primarily in childhood, is one of two diseases caused by the varicella zoster virus (vzv), the other being zoster, primarily in older age. Banz et al. estimate the annual economic burden of chickenpox at €188 million, some €154 million (82%) of which is attributable to work loss of parents caring for sick children. Medical costs make up the other 18%, with the vast majority of those costs related to the 90% of cases in children up to 12 years old. The costing approach in their contribution is based on a decision-analytic model that was previously used to evaluate childhood varicella vaccination in Germany by Banz et al. [2]. This model is named the "economic varicella vaccination tool for analysis" (EVITA) and was developed under a sponsorship by GlaxoSmithKline. The costing estimates published in this issue have been reported previously, as input data for EVITA, although less detail was provided [2]. …
Literatur
2.
Zurück zum Zitat Banz K, Wagenpfeil S, Neiss A et al (2003) The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21:1256–1267PubMed Banz K, Wagenpfeil S, Neiss A et al (2003) The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21:1256–1267PubMed
3.
Zurück zum Zitat Takahishi M (2001) 25 years' experience with the Biken Oka strain varicella vaccine. Pediatr Drugs 3:285–292 Takahishi M (2001) 25 years' experience with the Biken Oka strain varicella vaccine. Pediatr Drugs 3:285–292
4.
Zurück zum Zitat American Academy of Pediatrics, Committee on Infectious Diseases (2000) Varicella vaccine update. Pediatrics 105:135–141 American Academy of Pediatrics, Committee on Infectious Diseases (2000) Varicella vaccine update. Pediatrics 105:135–141
5.
Zurück zum Zitat Beutels P, Clara R, Tormans G et al (1996) Costs and benefits of routine varicella vaccination in German children. J Infect Dis 174:335–341 Beutels P, Clara R, Tormans G et al (1996) Costs and benefits of routine varicella vaccination in German children. J Infect Dis 174:335–341
6.
Zurück zum Zitat Thiry N, Beutels P, van Damme P, van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21:13–38 Thiry N, Beutels P, van Damme P, van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21:13–38
7.
Zurück zum Zitat Hjelmgren J, Berggren F, Andersson F (2001) Health economic guidelines—similarities, differences and some implications. Value Health 4:225–250CrossRefPubMed Hjelmgren J, Berggren F, Andersson F (2001) Health economic guidelines—similarities, differences and some implications. Value Health 4:225–250CrossRefPubMed
8.
Zurück zum Zitat Koopmanschap MA, Rutten FFH (1996) A practical guide for calculating indirect costs of disease. Pharmacoeconomics 10:460–466PubMed Koopmanschap MA, Rutten FFH (1996) A practical guide for calculating indirect costs of disease. Pharmacoeconomics 10:460–466PubMed
9.
Zurück zum Zitat Coudeville L, Paree F, Lebrun T et al (1999) The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17:142–151CrossRefPubMed Coudeville L, Paree F, Lebrun T et al (1999) The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17:142–151CrossRefPubMed
10.
Zurück zum Zitat Brisson M, Edmunds WJ (2002) The cost-effectiveness of varicella vaccination in Canada. Vaccine 20:1113–1125CrossRefPubMed Brisson M, Edmunds WJ (2002) The cost-effectiveness of varicella vaccination in Canada. Vaccine 20:1113–1125CrossRefPubMed
11.
Zurück zum Zitat Brisson M, Edmunds WJ, Gay NL et al (2000) Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect 125:651–669CrossRefPubMed Brisson M, Edmunds WJ, Gay NL et al (2000) Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect 125:651–669CrossRefPubMed
12.
Zurück zum Zitat Brisson M, Edmunds WJ, Gay NJ (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70:S31–S37CrossRefPubMed Brisson M, Edmunds WJ, Gay NJ (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70:S31–S37CrossRefPubMed
13.
Zurück zum Zitat Brisson M, Edmunds WJ, Gay NJ et al (2000) Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18:2775–278CrossRefPubMed Brisson M, Edmunds WJ, Gay NJ et al (2000) Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18:2775–278CrossRefPubMed
14.
Zurück zum Zitat Smith KJ, Roberts MS (2000) Antiviral therapies for herpes zoster Infections: are they economically justifiable. Pharmacoeconomics 18:95–104 Smith KJ, Roberts MS (2000) Antiviral therapies for herpes zoster Infections: are they economically justifiable. Pharmacoeconomics 18:95–104
15.
Zurück zum Zitat Seward JF, Jumaan AO, Galil K, Wharton M (2002) Varicella vaccine and shingles. JAMA 287:2211–222PubMed Seward JF, Jumaan AO, Galil K, Wharton M (2002) Varicella vaccine and shingles. JAMA 287:2211–222PubMed
16.
Zurück zum Zitat Edmunds WJ, Brisson M, Rose JD (2001) The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19:3076–3090CrossRefPubMed Edmunds WJ, Brisson M, Rose JD (2001) The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19:3076–3090CrossRefPubMed
17.
Zurück zum Zitat Thiry N, Beutels P, Shkedy Z, Vranckx R et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593CrossRefPubMed Thiry N, Beutels P, Shkedy Z, Vranckx R et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593CrossRefPubMed
18.
Zurück zum Zitat Nathwani D, Maclean A, Conway S, Carrington D (1998) Varicella infections in pregnancy and the newborn: a review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 36 [Suppl 1]:59–71 Nathwani D, Maclean A, Conway S, Carrington D (1998) Varicella infections in pregnancy and the newborn: a review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 36 [Suppl 1]:59–71
19.
Zurück zum Zitat Harger JH, Ernest JM, Thurau GR et al (2002) Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 185:422–427CrossRefPubMed Harger JH, Ernest JM, Thurau GR et al (2002) Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 185:422–427CrossRefPubMed
20.
Zurück zum Zitat Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545CrossRefPubMed Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545CrossRefPubMed
21.
Zurück zum Zitat Glantz JC, Mushlin AI (1998) Cost-effectiveness of routine antenatal varicella screening. Obstet Gynecol 91:519–528CrossRefPubMed Glantz JC, Mushlin AI (1998) Cost-effectiveness of routine antenatal varicella screening. Obstet Gynecol 91:519–528CrossRefPubMed
22.
Zurück zum Zitat Robert Koch-Institut (2003) Allgemeine Impfung gegen Windpocken (Varizellen)? Epidemiol Bull 11:79–82 Robert Koch-Institut (2003) Allgemeine Impfung gegen Windpocken (Varizellen)? Epidemiol Bull 11:79–82
23.
Zurück zum Zitat Van der Zeijst BAM, Dijkman MI, Kramers PGN, Luytjes W, Rümke HC, Welte R (2000) Naar een vaccinatieprogramma voor Nederland in de 21st e eeuw. Report by the National Institute of Public Health and the Environment: Bilthoven Van der Zeijst BAM, Dijkman MI, Kramers PGN, Luytjes W, Rümke HC, Welte R (2000) Naar een vaccinatieprogramma voor Nederland in de 21st e eeuw. Report by the National Institute of Public Health and the Environment: Bilthoven
24.
Zurück zum Zitat Seward JF, Watson BM, Peterson CL et al (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287:606–611PubMed Seward JF, Watson BM, Peterson CL et al (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287:606–611PubMed
Metadaten
Titel
Do costs of varicella justify routine infant vaccination?
Pharmacoeconomic and clinical considerations
verfasst von
M. J. Postma
J. M. Bos
R. Welte
R. de Groot
W. Luytjes
H. C. Rümke
P. Beutels
Publikationsdatum
01.02.2004
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 1/2004
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-003-0201-6

Weitere Artikel der Ausgabe 1/2004

The European Journal of Health Economics 1/2004 Zur Ausgabe